These receptors together with ki67, providing direct observation on the molecular underpinnings of the tumor, have been widely studied and are at the basis of the choose for personalized treatments: for example, patients with HER2+ cancer have been found to be quite effectively treated with trastuzumab and lapatinib [18]; ki67 has been identified as a prognostic and predictive marker in hormone receptor positive breast cancer [19]. Here, MKI67 is linked to breast cancer.